Company Nyrvusano Pharmaceuticals Srl with Fiscal Code 36694353
recorded a turnover of 2024 of
1.977.084,
with a net profit of
733.674
and having an average number of employees of
20.
The company operates in the field of Comerţ cu ridicata nespecializat having the NACE code 4690.
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 48.3%, from 1.340.685 euro in the year 2023, to 1.977.084 euro in 2024.
The Net Profit increased by 241.834 euro, from 494.604 euro in 2023, to 733.674 in the last year.
Check the financial reports for the company - Nyrvusano Pharmaceuticals Srl
Financial Rating - NYRVUSANO PHARMACEUTICALS SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Nyrvusano Pharmaceuticals Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Nyrvusano Pharmaceuticals Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Nyrvusano Pharmaceuticals Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
1.522.911 euro in 2024 which includes Inventories of
102.524 euro, Receivables of
715.620 euro and cash availability of
704.767 euro.
The company's Equity was valued at
1.325.602 euro, while total Liabilities amounted to
290.343 euro.
Equity increased by 414.250 euro, from 916.474 euro in 2023, to 1.325.602 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Nyrvusano Pharmaceuticals Srl